Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$76,358.00+0.81%ETH$2,445.11+2.05%GOLD$4,385.80-0.32%OIL$101.20-0.70%
Smart Investors Daily
XL

NASDAQ · XLO

Xilio Therapeutics, Inc.

Healthcare · Biotechnology

$8.98

Up+$0.06 (+0.67%)

Updated Sep 17, 2026, 10:46 PM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
37.56M
P/E ratio
-2.44
Dividend yield
0.00%
52-week range
$6.47 – $12.74
Volume
11.53K
Avg. volume
620.67K

Price performance

XLO price history

1M range · 20 trading sessions · Daily adjusted prices

XLO closed at $8.98 after 20 trading sessions, down 4.57% for the selected period.

Last close
$8.98
Period change
-4.57%
Period low
$8.84
Period high
$9.41
Daily close
View OHLC price history
XLO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$9.02$9.02$8.93$8.9811.53K
Sep 15, 2026$8.9301$9.03$8.9301$9.0317.35K
Sep 14, 2026$9.06$9.21$8.93$8.9310.26K
Sep 11, 2026$8.93$9.49$8.93$8.935.15K
Sep 10, 2026$8.95$9.00$8.93$8.9311.8K
Sep 9, 2026$8.91$9.00$8.8001$8.978.98K
Sep 8, 2026$9.03$9.11$8.81$8.919.99K
Sep 4, 2026$9.2308$9.2308$8.81$9.007.64K
Sep 3, 2026$8.94$9.10$8.7211$9.026.57K
Sep 2, 2026$9.1417$9.1417$8.84$8.844.65K
Sep 1, 2026$8.57$9.2481$8.57$8.8831.14K
Aug 31, 2026$9.00$9.27$8.90$8.9514.57K
Aug 28, 2026$8.995$9.28$8.995$9.003.64K
Aug 27, 2026$8.785$9.115$8.785$9.019.03K
Aug 26, 2026$9.09$9.145$8.9221$9.057.71K
Aug 25, 2026$9.16$9.30$9.08$9.085.9K
Aug 24, 2026$9.32$9.32$9.17$9.192.29K
Aug 21, 2026$9.21$9.23$9.07$9.235.23K
Aug 20, 2026$9.27$9.27$9.1101$9.236.38K
Aug 19, 2026$9.44$9.48$9.1185$9.416.87K

Latest XLO news

The latest Smart Investors Daily articles mentioning XLO.

Stock researchCompany · Overview

XLO research

Overview

Company profile and research snapshot.

Company profile

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.00
Implied upside
—
Analysts
6
XLO recent ratings
DateFirmRatingTarget
Aug 6, 2025Leerink PartnersOutperform—
Nov 8, 2024Raymond JamesOutperform—
May 30, 2023Chardan CapitalBuy—
May 11, 2023Chardan CapitalBuy—
Jan 27, 2023Morgan StanleyOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $8.88

Yahoo · Aug 12, 2026

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1; IND applications anticipated in the second half of 2027 Cash runway into the first quarter of 2028 expected to support key milestones across pipeline of next generation multi-specific I-O therapies WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) --

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By